Recent developments include leadership appointments, research collaborations, facility certifications, market expansion, and capital raises.

• Cuprina Holdings appointed Dr. Ronald A. Sherman as Medical and Scientific Director, enhancing bio-therapeutic expertise in July 2025 [N1].
• The company advanced collagen peptide research through collaborations with Singapore institutions as of June 2025 [N2].
• Cuprina expanded its chronic wound care offerings and entered the medicinal leech market in the MENA and GCC regions in June 2025 [N3].
• Completed sale of 450,000 additional Class A Ordinary Shares, raising $13.8 million in IPO follow-up financing in May 2025 [N4].
• Completed construction of IVF media production facility and achieved ISO 13485 certification in Singapore in May 2025 [N5].

Cuprina has established a foothold in the niche chronic wound care market with innovative, nature-based medical devices. The company’s successful IPO and subsequent capital raise provide resources for expansion into Southeast Asia, China, the Middle East, and other markets. Collaborations with research institutions and the appointment of experienced scientific leadership enhance its R&D capabilities. Achieving ISO 13485 certification and completing specialized production facilities demonstrate operational progress. Expansion into new product areas such as medicinal leech therapy and collagen peptides diversifies offerings. These factors support the company’s ability to grow its presence and product portfolio in specialized medical and cosmeceutical markets.

Cuprina reported a net loss of $3.63 million in 2025 on modest revenue of $38,789, indicating ongoing operating losses and limited current scale. The company faces risks related to market acceptance, regulatory approvals, and competition in the chronic wound care and medical device sectors. Its reliance on educating healthcare practitioners for product adoption may require sustained investment. Geographic expansion and new product development carry execution risks. Liquidity and capital needs may increase if operating losses continue. The company’s financial position and operating results reflect early-stage commercialization with inherent uncertainties.

Cuprina's moat is based on its specialized nature-based bioactive wound care products, including Maggot Debridement Therapy, which require specific expertise and regulatory navigation. The company’s in-house manufacturing capabilities, research collaborations, and ISO certifications support product quality and regulatory compliance. Its focus on educating healthcare practitioners and building brand awareness in niche chronic wound care markets contributes to customer retention and adoption. Geographic diversification and ongoing R&D efforts further support competitive positioning. However, the company operates in a specialized and evolving medical device market with regulatory and competitive challenges.

• Market Acceptance and Adoption Risk: Cuprina’s revenue growth depends on educating healthcare practitioners and gaining acceptance of its specialized wound care products, which may require significant time and resources.
• Regulatory and Compliance Risk: The company operates in regulated medical device markets requiring ongoing compliance and approvals, which may delay product launches or increase costs.
• Financial and Liquidity Risk: Operating losses and limited revenue scale may necessitate additional financing, which could dilute shareholders or increase debt obligations.
• Competitive Risk: The chronic wound care market includes established competitors and evolving technologies, posing challenges to Cuprina’s market share and pricing.
• Execution Risk in Geographic Expansion: Expanding into new markets such as Southeast Asia, China, and the Middle East involves operational, regulatory, and cultural challenges that may impact growth plans.

• Cuprina Holdings (Cayman) Limited is a Cayman Islands exempted company incorporated in 2023 and is the holding company of subsidiaries operating primarily in Singapore, Malaysia, China, Hong Kong, the United States, and other regions [S1].
• The company manufactures, supplies, and sells medical devices focused on chronic wound care, primarily Maggot Debridement Therapy (MDT) products, which are nature-based bioactive advanced wound dressings derived from sustainable sources [S1].
• Cuprina's products have applications in medical, cosmeceutical, and nutraceutical industries and are currently sold directly in Singapore and Hong Kong [S1].
• The company operates two reportable segments: Maggot Debridement Therapy Product and Cosmeceutical Product [S1].
• Revenue is generated primarily from sales of chronic wound care products to hospitals and clinics, with a focus on educating healthcare practitioners to drive product adoption [S1].
• Cuprina completed its IPO on April 11, 2025, issuing 3,000,000 Class A Ordinary Shares at $4.00 per share, raising net proceeds of approximately $9.18 million, and completed an over-allotment sale of 450,000 shares on May 8, 2025, raising an additional $1.8 million [S1][N4].
• The company raised aggregate net proceeds of $10.85 million from the IPO including the over-allotment, after deducting offering costs of approximately $2.95 million [S1][N4].
• IPO proceeds have been partially used for growth and expansion into new markets including Southeast Asia (excluding Singapore), Hong Kong, mainland China, and the Middle East; research and development; brand building; equipment and infrastructure investment; loan repayment; and general corporate purposes [S1].
• Cuprina completed construction of an IVF media production facility and achieved ISO 13485 certification in Singapore as of May 2025 [N5].
• The company expanded its chronic wound care offerings and entered the medicinal leech market in the MENA and GCC regions as of June 2025 [N3].
• Cuprina advanced collagen peptide research through collaborations with Singapore institutions as of June 2025 [N2].
• Dr. Ronald A. Sherman was appointed as Medical and Scientific Director in July 2025, expanding the company's bio-therapeutic expertise [N1].
• As of December 31, 2025, Cuprina reported cash and cash equivalents of $2,423,760 USD, current assets of $5,699,428 USD, and current liabilities of $2,421,996 USD, resulting in a current ratio of 2.35 and a cash ratio of 1.0 [S1].
• For the fiscal year ended December 31, 2025, the company reported revenue of $38,789 USD and a net loss of $3,633,248 USD [S1].
• Basic and diluted earnings per share for 2025 were negative $22.83 SGD per share [S1].
• The company has not had any defaults on indebtedness or dividend arrearages [S1].
• Cuprina manages credit risk by dealing with high credit rating counterparties and monitors receivables to minimize bad debts [S1].
• Interest rate risk arises primarily from borrowings and lease liabilities; liquidity risk is managed by maintaining adequate cash and bank balances [S1].
• Foreign currency risk is minimal as transactions are substantially in Singapore Dollars [S1].
• The company has adopted a Code of Business Conduct and Ethics and insider trading policies applicable to directors, officers, and employees [S1].
• Cuprina has not reported any material cybersecurity incidents affecting its business [S1].
• The company’s business model visibility is supported by detailed segment reporting, geographic diversification, and customer concentration disclosures [S1].
• Cuprina’s revenue is principally derived from operations in Singapore, with assets located in Singapore, Malaysia, and the USA [S1].
• The company’s financial statements are prepared in accordance with US GAAP and SEC regulations [S1].